Ekaterina Bychkova

Ms. Ekaterina Bychkova


Research Focus & Metrics

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
EBEkaterina Bychkova
Ekaterina Bychkova
MDMarina Dorofeeva
Marina Dorofeeva
ALAleksandr Levov
Aleksandr Levov
AKAlexey Kislyakov
Alexey Kislyakov
KKKristina Karandasheva
Kristina Karandasheva
KAKirill Anoshkin
Kirill Anoshkin
Patients with tuberous sclerosis complex present with cognitive, behavioral, and psychiatric impairments, such as intellectual disabilities, autism spectrum disorders, and drug-resistant epilepsy. It has been shown that these disorders are associated with the presence of cortical tubers. Tuberous sclerosis complex results from inactivating mutations in the TSC1 or TSC2 genes, resulting in hyperactivation of the mTOR signaling pathway, which regulates cell growth, proliferation, survival, and autophagy. TSC1 and TSC2 are classified as tumor suppressor genes and function according to Knudson’s two-hit hypothesis, which requires both alleles to be damaged for tumor formation. However, a second-hit mutation is a rare event in cortical tubers. This suggests that the molecular mechanism of cortical tuber formation may be more complicated and requires further research. This review highlights the issues of molecular genetics and genotype–phenotype correlations, considers histopathological characteristics and the mechanism of morphogenesis of cortical tubers, and also presents data on the relationship between these formations and the development of neurological manifestations, as well as treatment options.

31 October 2024 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
TBTatiana S. Belysheva
Tatiana S. Belysheva
EZEkaterina Zelenova
Ekaterina Zelenova
NSNatalia Semenova
Natalia Semenova
ESElena V. Sharapova
Elena V. Sharapova
VSVera Semenova
Vera Semenova
VSVladimir Strelnikov
Vladimir Strelnikov
Background. Proteus syndrome is extremely rare congenital multisystem disease with high variability in clinical manifestations. Its prevalence is unknown, there are less than 200 cases in the world literature. The syndrome is a classic example of somatic mosaicism, and all target drugs for its management are based on it. Clinical case description. This article describes two clinical cases with somatic variants of the nucleotide sequence in the AKT1 gene, mosaic form, revealed by the NGS method. Target drug (mTOR-inhibitors group) was assigned in one case. Conclusion. The description of the phenotypic features of patients with Proteus syndrome is crucial as this pathology is very rare. It is necessary to increase the awareness of clinicians about this disease to develop a plan for dynamic follow-up with consideration to life-threatening complications (malignant tumors and thrombembolia risk). Genetic verification of Proteus syndrome is mandatory nowadays as target therapy is actively developed and implemented, thus, revision of clinical guidelines is recommended.

Verified
Journal Article
Open access
PDF file
EBEkaterina Bychkova
Ekaterina Bychkova
NSNatalia Semenova
Natalia Semenova
GSGarik Sagoyan
Garik Sagoyan
SASeyfulla V. Alimov
Seyfulla V. Alimov
AZAleksandr Evgenevich Zhigulin
Aleksandr Evgenevich Zhigulin
VSVladimir Strelnikov
Vladimir Strelnikov
Segmental overgrowth and vascular malformations comprise a group of diseases caused by postzygotic variants in genes that regulate cell growth, proliferation, and angiogenesis. The best-characterized group is the PIK3CA-related overgrowth spectrum (PROS), which includes syndromes sharing variants in the PIK3CA gene. Beyond PIK3CA, the genes involved fall into two mechanistically distinct groups, with gain-of-function (GNAQ, GNA11, TEK, AKT1, AKT3, MTOR, PIK3R1) and loss-of-function (RASA1, GLMN, PTEN) causative variants. What remains poorly established is how effectively a molecular diagnosis is actually achieved in routine practice, and how this depends on the referral clinical diagnosis. By targeted panel deep sequencing in patients with segmental overgrowth and/or a vascular malformation, we have identified at least one pathogenic / likely pathogenic (P/LP) genetic variant in 266 of the 375 successfully tested patients, giving an overall diagnostic yield of 70.9%. The yield was 63.5% in patients with isolated overgrowth (94 of 148), 75.0% in patients with an isolated vascular malformation (111 of 148) and 77.2% in patients with a combined or syndromic phenotype (61 of 79). The 277 P/LP variants identified were distributed across 17 genes; PIK3CA accounted for 141 variants (50.9%), GNAQ for 44 (15.9%), TEK for 31 (11.2%), RASA1 for 15 (5.4%) and GNA11 for 11 (4.0%); these five genes together accounted for 87.4% of the variants. The spectrum was highly concentrated: the ten most frequent variants accounted for 57.0% of the P/LP variants, with GNAQ variant p.Arg183Gln (15.2%) and PIK3CA hotspot variants p.Glu542Lys (8.7%), p.Glu545Lys (6.9%), and p.His1047Arg (7.6%). In several genes, variants were restricted to specific regions: in GNAQ and GNA11 to two codons, 183 and 209 (98.2% of all findings), and in TEK to the 3′-terminus. Considered together with the referral diagnosis, the distribution of variants, their allele fractions and their mechanisms of pathogenicity suggest molecular testing strategies.